Combining Internal Expertise With Strategic Partnerships

Through internal capabilities and strategic partnerships, we will utilize the best available research and development platforms to develop innovative therapies and pioneering product advances."
- Larry Stern, Chairman and CEO, Talecris Biotherapeutics

New Product Development

Talecris continues to leverage research and development strengths to seek additional co-development partners and further strengthen our product pipeline. Working together, Talecris and our strategic development partners allow Talecris innovations to reach even more patients around the world.

Bausch & Lomb — Current co-development with Bausch & Lomb involves both plasma-derived and recombinant Plasmin, and explores potential use for certain types of ocular procedures.

Emergent BioSolutions — An exclusive manufacture and supply agreement between Talecris Biotherapeutics and Emergent BioSolutions involves the development of a new immunoglobulin for inclusion in the national stockpile for the treatment of anthrax exposure.